Lupin has received final approval for its Carbidopa Tablets, 25 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Aton Pharma, Inc.’s Lodosyn Tablets, 25 mg. Carbidopa Tablets, 25 mg had annual sales of approximately $21.9 million in the US, as per IMS MAT June 2017.
Lupin’s Carbidopa Tablets, 25 mg is the AB rated generic equivalent of Aton Pharma, Inc.’s Lodosyn Tablets, 25 mg. It is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
